Wikipedia

Acquired haemophilia

Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII. These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.[1]

Its incidence is approximately 1.5 cases/million/year.[2] The distribution is bimodal with a first period occurrence between 20 and 30 years old, which mainly corresponds to women who develop this disorder in the postpartum, and a second peak between 68 and 80 years old, corresponding to the majority of patients, with no sex difference.[3]

An underlying medical condition can be identified in up to 50% of patients, including cancer either solid or hematologic; autoimmune diseases such as rheumatoid arthritis, Sjögren syndrome, or bullous pemphigoid; administration of drugs and pregnancy. However, AHA can also emerge in elderly people without any risk factors.[4][5][6]

Overall mortality rate in AHA is varies from 20% to 70% depending on the series, attributed to the underlying disorder in about 50% of the cases, infections (5-15%) and major bleeding episodes (4%)[7][8][9]

The reason for this loss of tolerance to self-factors is still unclear. There may be different involved mechanisms, such as the presence of certain gene polymorphisms (e.g., HLA, CTLA4) and/or autoreactive CD4+ T lymphocytes.[10][11]

Clinical features edit

Due to the variable bleeding phenotype of this disorder, the clinical picture ranges from life-threatening and traumatic bleeds to mild or no bleeding tendency. In some cases, it is first noted after a surgical procedure, however, most occur spontaneously without apparent provocation. As patients with AHA are often elderly, co-morbidities and co-medications such as anti-platelet agents may also influence the clinical profile and require an individualized therapeutic approach. Symptomatic patients often present with large hematomas, extensive ecchymosis or severe mucosal bleeding, including epistaxis, gastrointestinal bleeding, and haematuria. In contrast with what happens to patients with congenital haemophilia, spontaneous hemarthroses are unusual.[12] Women with postpartum factor VIII inhibitors usually present with abnormal vaginal bleeding.[13]

Diagnosis edit

Any acute or recent onset of bleeding symptoms in a patient with no previous history of bleeding, especially in elderly or post-partum patients, and an unexplained isolated prolonged activated partial thromboplastin time (aPTT) suggest the diagnosis of AHA, and need further investigation. The differential diagnosis in prolonged aPPT with a normal prothrombin time (PT) includes factor deficiencies, lupus anticoagulant or heparin therapy.[14]

The first step to distinguish between factor deficiency and the presence of an inhibitory substance is to perform a mixing test,[15] in which patient plasma and normal plasma are mixed and aPTT measured; correction of prolonged aPTT suggests a factor deficiency while persistent prolongation indicates the presence of an inhibitor. Prolongation of the aPTT in a mixture of patient and normal plasma after a 1-2 h incubation compared to an immediate mix is typical of FVIII autoantibodies, as FVIII inhibitors are time and temperature-dependent.

The diagnosis is confirmed by the subsequent identification of reduced FVIII levels with evidence of FVIII neutralising activity (titrated using the Bethesda assay or the Nijmegen modification).[16]

Treatment edit

Patients with acquired coagulation factor inhibitors should be treated jointly with haemophilia centres experienced in the management of inhibitors. Initial treatment consists of four steps:[17]

  1. Prevention of bleeding events, avoiding or minimizing actions that might provoke bleeding such as intramuscular injections, invasive procedures and use of antiplatelet and nonsteroidal anti-inflammatory agents.
  2. Treatment of the underlying disorder.
  3. Therapy of bleeding
  4. Antibody eradication

Therapy of bleeding edit

Anti-haemorrhagic treatment should be initiated in patients with AHA and active severe bleeding symptoms irrespective of inhibitor titre and residual FVIII activity. First-line treatment includes by-pass agents (activated prothrombin complex concentrates [aPCC] Factor Eight Inhibitor Bypassing Activity [FEIBA] and recombinant activated factor VII rFVIIa). Both treatments are effective and there is no evidence for the use of one product in preference to the other. Therapy should be continued until bleeding is controlled and management must generally rely on the clinical assessment as there are no validated laboratory tests to determine therapeutic levels. The main concern about the use of these agents is the appearance of thrombotic events.[18] Tranexamic acid is a useful adjunct therapy but concerns about its concomitant use with FEIBA exist.

A recombinant porcine FVIII molecule has recently been approved to treat bleeding episodes, with similar pharmacokinetics to human FVIII and the possibility of laboratory measurement and dose-adjustment.[19]

Alternative treatments if first-line treatment is unavailable or fails include human FVIII, DDAVP, intravenous immunoglobulin, immunoadsorption and plasmapheresis.

Antibody eradication edit

All patients diagnosed with AHA should receive immunosuppressive therapy immediately following diagnosis with prednisolone either alone or combined with cyclophosphamide, what has a complete remission rate of 70-80%.

If there is no response within 3–5 weeks, second-line therapies should be considered. The most common second-line treatment is with rituximab combined with other agents. Alternative options are calcineurin inhibitors, multiple immunosuppressive agents and immune tolerance protocols.

Most immunosuppressive drugs are associated with side effects, including neutropenia-related infections and sepsis.

The relapse rate after a first complete remission has been estimated at about 20%[20]

See also edit

References edit

  1. ^ Hunth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of pacients with acquired hemophilia A. Haematologica. 2009; 94: 566-75.
  2. ^ Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al.Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-7.
  3. ^ Franchini M, Vaglio S, Marano G, Mengoli C, Gentili S, Pupella S, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology. 2017; 22: 514-20.
  4. ^ Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981;45:200-3.
  5. ^ Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia.Blood 1993;81:1513-20.
  6. ^ Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005;80:55-63.
  7. ^ Knoelb P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10: 622-31.
  8. ^ Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009; 20: 517-23.
  9. ^ Delgado J, Jiménez-Yuste V, Hernández-Navarro F, Villar A. Acquired haemophilia: review and meta analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121: 21-35.
  10. ^ Pavlova A, Zeitler H, Scharrer I, et al. HLA genotype in patients with acquired haemophilia A. Haemophilia 2010; 16:107.
  11. ^ Wootla B, Desirazu N, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri S. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies. Clinic Rev Allerg Immunol. 2009; 37: 97-104.
  12. ^ Mingot-Castellano ME, Núñez R, Rodríguez-Martorell FJ. Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc). 2017; 148: 314-22.
  13. ^ Nemes L, Tengborn L, Collins PW, Baudo F, Huth-Kuehne A, Knoebl P, et al. Acquired Haemophilia and pregnancy/postpartum- a Report from an European Acquired Registry. Blood. 2010; 116: 717.
  14. ^ Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Mingot Castellano ME, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes. 2010; 3: 161-8.
  15. ^ Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975; 34: 612
  16. ^ Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 73: 247-51.
  17. ^ W Collins, P., Chalmers, E., Hart, D., Jennings, I., Liesner, R., Rangarajan, S., Talks, K., Williams, M. and R. M. Hay, C. (2013), Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol, 162: 758-773. doi:10.1111/bjh.12463
  18. ^ Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2:1700-1708.
  19. ^ Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21:162.
  20. ^ Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al.Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Acquired_haemophilia&oldid=1113487399"